These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34219361)

  • 1. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
    Gastaldelli A; Sabatini S; Carli F; Gaggini M; Bril F; Belfort-DeAguiar R; Positano V; Barb D; Kadiyala S; Harrison S; Cusi K
    Liver Int; 2021 Nov; 41(11):2659-2670. PubMed ID: 34219361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone in the treatment of NASH: the role of adiponectin.
    Gastaldelli A; Harrison S; Belfort-Aguiar R; Hardies J; Balas B; Schenker S; Cusi K
    Aliment Pharmacol Ther; 2010 Sep; 32(6):769-75. PubMed ID: 20662773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
    J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
    Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
    Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals.
    Saponaro C; Sabatini S; Gaggini M; Carli F; Rosso C; Positano V; Armandi A; Caviglia GP; Faletti R; Bugianesi E; Gastaldelli A
    Liver Int; 2022 Nov; 42(11):2418-2427. PubMed ID: 35900229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review.
    Polyzos SA; Mantzoros CS
    Metabolism; 2016 Sep; 65(9):1297-306. PubMed ID: 27506737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
    Boettcher E; Csako G; Pucino F; Wesley R; Loomba R
    Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    Shen W; Middleton MS; Cunha GM; Delgado TI; Wolfson T; Gamst A; Fowler KJ; Alazraki A; Trout AT; Ohliger MA; Shah SN; Bashir MR; Kleiner DE; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Zhou J; Sirlin CB; Lavine JE
    J Hepatol; 2023 Feb; 78(2):238-246. PubMed ID: 36368598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
    Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.